Liver Cancer: Our Clinical Trials

Title	Investigator
A Phase I Study of GC33 plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma [Protocol 10-021]	Abou-Alfa, Ghassan, MD
A Phase IB Study of Vismodegib in Patients with Liver Cancer with Varying Degrees of Kidney and Liver Function [Protocol 12-031]	Abou-Alfa, Ghassan, MD
A Phase II Study of Everolimus, Leuprolide/Letrozole, and Everolimus/Leuprolide/Letrozole in Patients with Inoperable Fibrolamellar Hepatocellular Carcinoma [Protocol 11-211]	Abou-Alfa, Ghassan, MD
A Phase II Study of GC33 in Patients with Advanced Hepatocellular Carcinoma [Protocol 12-145]	Abou-Alfa, Ghassan, MD
A Phase II Study of Sorafenib in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, or Papillary Thyroid Cancer [Protocol 12-139]	Trippett, Tanya, MD
A Phase II Study of Sorafenib plus Doxorubicin in Patients with Liver Cancer that Continued Growing with Sorafenib Therapy [Protocol 12-259]	Abou-Alfa, Ghassan, MD
A Phase III Study of ADI-PEG20/Supportive Care or Placebo/Supportive Care in Patients with Advanced Liver Cancer [Protocol 11-081]	Abou-Alfa, Ghassan, MD
A Phase III Study of Sorafenib plus Doxorubicin versus Sorafenib Alone in Patients with Advanced Hepatocellular Cancer [Protocol 11-039]	Abou-Alfa, Ghassan, MD
Examination of Tissue from Ablated Malignant Liver Metastases to Predict Outcome [Protocol 09-122]	Sofocleous, Constantinos, MD, PhD
Treatment of Children with All Stages of Hepatoblastoma [Protocol 10-046]	Kobos, Rachel, MD

Title